Table 1.
Clinical features and genetic aberrance of MCG reported in literature.
| Authors | Publish year | Number of cases | Gender | Age (median and range)/yr | S/M MCG | Pathology | WHO grade | Surgery | Radiotherapy | Chemotherapy | OS(median and range)/months | Genetic aberrance | Source mutations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solitare et al. (42) | 1962 | 1 | f | 15 | na | DA | 2 | r | n | n | 60 | na | na |
| Batzdorf et al. (6) | 1963 | 2 | m2 | 44/62 | na | GBM1/AA1 | 4/3 | r2 | y2 | y2 | 24/30 | na | na |
| Solomon et al. (43) | 1969 | 1 | f | 32 | S | OA&DA | 2&2 | r | y | n | 36 | na | na |
| Chadduck et al. (44) | 1983 | 1 | m | 63 | S | GBM | 4 | b | y | n | 5 | na | na |
| Kato et al. (45) | 1990 | 1 | f | 59 | S | AA | 3 | r | y | n | 1 | na | na |
| Pell et al. (46) | 1991 | 1 | m | 11 | S | GBM | 4 | b | y | n | 1 | na | na |
| Philippon et al. (47) | 1992 | 1 | f | 53 | na | PA&GBM | 1&4 | y | n | n | 8 | na | na |
| Mamelak et al. (48) | 1994 | 5 | m4/f1 | 11 (3–43) | M5 | PA4,O&PA1 | 1,2&1 | r3/b2 | y5 | y3/n2 | all alive 30 (21–37) | na | na |
| Sim et al. (49) | 1999 | 1 | f | 11 | S | O&PA | 2&1 | r | n | n | alive at 30 | na | na |
| van Nielen et al. (50) | 1999 | 1 | m | 28 | S | DA | 2 | b | y | n | Alive at 6 | na | na |
| Franco et al. (51) | 2000 | 2 | f2 | 39/52 | M/S | GBM/DA | 4/2 | r/b | y/n | y/n | 20/16 | na | na |
| Reis et al. (7) | 2001 | 1 | m | 54 | M | AA&GBM | 3&4 | r | y | y | 10yr | TP53, PTEN, EGFR, p16 deletion | na |
| Zamponi et al. (8) | 2001 | 1 | m | 12 | S | AA | 3 | r | y | n | na | na | na |
| Synowitz et al. (38) | 2002 | 1 | m | 68 | S | GBM | 4 | r | y | n | 0.5 | na | na |
| Jawahar et al. (52) | 2003 | 1 | f | 73 | M | GBM | 4 | b | n | n | 6 | na | na |
| Salvati et al. (10) | 2003 | 25 | m15/f10 | 53(31-68) | S21M4 | GBM18/AA7 | 4/3 | r15/b10 | y21/n4 | y19/n6 | 8(0.5-18) | na | na |
| Kaku et al. (53) | 2004 | 1 | m | 45 | na | AA | 3 | r | y | y | Alive at 5 | na | na |
| Saikali et al. (54) | 2005 | 1 | f | 30 | S | PA | 1 | r | n | y | 36 | na | na |
| Iza et al. (55) | 2006 | 1 | f | 62 | M | GBM | 4 | r | y | y | 26 | na | na |
| Ampil et al. (56) | 2007 | 1 | na | 56 | S | AA | 3 | b | y | n | 2 | na | na |
| Tsutsumi et al. (31) | 2008 | 1 | f | 8 | M | DA&GBM | 2&4 | r | n | y | 5 | na | na |
| Colavolpe et al. (57) | 2008 | 1 | m | 44 | S | GBM | 4 | r | n | y | 18 | MGMT, CD133 | na |
| Vergani et al. (58) | 2009 | 1 | f | 23 | S | DA&O | 2&2 | r | n | y | alive at 84 | loss of 19q | na |
| Salunke et al. (59) | 2010 | 1 | m | 50 | S | GBM | 4 | r | y | n | 18 | na | na |
| Hassaneen et al. (60) | 2011 | 9 | m7/f2 | 48(na) | S5M4 | GBM | 4 | r9 | y5/n4 | y5/n4 | 12.9(na) | na | na |
| Sakai et al. (61) | 2011 | 1 | m | 20 | S | PA | 1 | b | n | n | alive at 48 | syn-, nf-, TP53 - | na |
| di Russo et al. (62) | 2013 | 18 | m8/f10 | 66.5(37-78) | S15M3 | GBM14/AA4 | 4/3 | r18 | y7/n11 | y17/n1 | 10(4-29) | na | na |
| Terakawa et al. (63) | 2013 | 5 | m3/f2 | 32(23-35) | S | O3,DA1,O&DA1 | 2,2,2&2 | r5 | n5 | n5 | all alive 30(11-138) | IDH1 mutation | na |
| Kanoke et al. (28) | 2013 | 1 | m | 30 | M | PA&OA | 1&2 | r | y | y | alive at 14yr | BRAF amplification in 1, BRAF V600E mutation in 1, IDH1 R132H in 1 | na |
| Garcia et al. (64) | 2013 | 1 | f | 38 | S | O | 2 | r | n | n | alive at 36 | 1p/19q loss, 10q and 7p loss, IDH1 mutation | na |
| Wan et al. (65) | 2014 | 1 | m | 47 | M | GBM | 4 | r | y | y | 3 | na | na |
| Yan et al. (25) | 2015 | 5 | m4/f1 | 56(38-70) | S4M1 | GBM5 | 4 | r5 | y4/n1 | y4/n1 | 7(4-30) | MGMT,1p19q mutations in 1 | na |
| Sridharan et al. (40) | 2015 | 1 | m | 49 | S | DA | 2 | r | n | y | alive at 24 | GG: IDH1 wildtype; LGA: PDGFRA, APC(E582A), CHEK2, ETV6, MLL2, SDHB, SF3B1 |
na |
| Ma et al. (41) | 2015 | 1 | m | 20 | S | GG&PA | 1&1 | r | n | n | alive at 48 | na | na |
| de Eulate-Beramendi et al. (33) | 2016 | 1 | f | 83 | S | GBM | 4 | r | n | n | 0.5 | na | na |
| Inoue et al. (66) | 2016 | 1 | m | 27 | S | GBM | 4 | b | y | y | 9 | TP53, EGFR | na |
| Schroeder et al. (67) | 2016 | 1 | m | 47 | S | GBM | 4 | r | y | y | 12 | TP53 R175H, HDAC2, MARCKS, HDAC2A/2B deletion, MTSS1 loss, MET amplification, EGFRvIII mutation | na |
| Corrivetti et al. (68) | 2016 | 1 | m | 41 | S | DA | 2 | r | n | y | alive at 12 | IDH1 mutation, with no 1p19q codeletion; IDH1 mutation, with 1p19q codeletion |
na |
| Cabrera-Aldana et al. (34) | 2017 | 1 | m | 40 | S | GBM | 4 | b | n | n | 1.5 | na | na |
| Abou-el-ardat et al. (9) | 2017 | 6 | m5/f1 | 70 (56–74) | S6 | GBM | 4 | na | na | na | na | PTEN, TP53, EGFR, and CDKN2A/B | TERTp in 5,PTEN in 2, EGFR in 1,CDKN2A in 1 |
| Grosu et al. (69) | 2017 | 1 | m | 30 | S | OA | 2 | b | n | n | 0 | IDH1 nuclear positive | na |
| Picart et al. (24) | 2018 | 2 | m | 61-83 | S2 | GBM | 4 | b2 | n2 | n2 | 1.5(1-2) | MGMT,EGFR;MGMT | na |
| Hayes et al. (70) | 2018 | 4 | m3/f1 | 29(21-44) | S3/M1 | DA2,DA&AA1,O&DA2 | 2,2&3,2&2 | r4 | y2/n2 | y2/n2 | all alive 7.2yr(5.7yr-10yr) | IDH1,TP53,ARTX | IDH1 R132H in 2, TP53 in 1 |
| Lahmi et al. (71) | 2019 | 3 | m3 | 63(58-65) | na | GBM | 4 | na | y3 | y3 | 5(4-7) | na | na |
| Kohno et al. (37) | 2020 | 1 | m | 78 | S | Epithelioid GBM | 4 | r | y | y | Alive at 6 | TERTp | na |
| Guerrini et al. (72) | 2021 | 16 | m11/f5 | 67.5(44-83) | na | GBM14/AA1/AO1 | 4/3/3 | b5/r11 | y11/n5 | y11/n5 | 7(1-24) | IDH1 in 1, ATRX in 3, EGFR in 15, TP53 in 14 | na |
| Enomoto et al. (73) | 2021 | 1 | f | 4 | S | GBM | 4 | b | y | y | 19 | IDH wildtype | na |
| Agopyan-Miu et al. (74) | 2021 | 1 | m | 23 | S | O | 2 | r | y | y | alive at 27 | IDH1,PDGFR-A | TERT promoter, IDH1 R132H in 1; TERT promoter, IDH1 R132G in 1 |
(AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, DA diffuse astrocytoma, GA gemistocytic astrocytoma, GBM Glioblastoma multiforme, GG Ganglioglioma, O oligodendroglioma, OA oligoastrocytoma, PA pilocytic astrocytoma, b biopsy, r resection, S synchronous, M metachronous, OS overall survival, y yes, n now, m male, f female, na not available, H high, L low, yr years) Annotation: The 2021 WHO Classification of CNS Tumors has cancelled the terminology of GBM and AA, and substitutes them with Glioblastoma, IDH-widetype, or Astrocytoma, IDH-mutant, grade 3 and 4. However, due to the referring cases in the table are mostly reported before the publication of the new classification, the terminologies of GBM and AA are continued to use.